Drug intelligence / Profile preview

LASEP1 siRNA

Development stage
Preclinical
Lead developer
Shiga University of Medical Science
Modality
Chemically Modified siRNA → Small Interfering RNA (siRNA) → Small RNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics, Conjugated siRNA → Small Interfering RNA (siRNA) → Small RNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics
01

Overview

LASEP1 siRNA is a small interfering RNA therapeutic candidate designed to target the mRNA of Lung Cancer-Associated Serum Protein 1 (LASEP1). LASEP1 is a secreted growth factor that is significantly overexpressed in both non-small cell lung cancer (NSCLC) and small cell lung cancer (SCLC), where it correlates with poor patient prognosis. The siRNA functions by inducing the degradation of LASEP1 mRNA, thereby reducing the secretion of the LASEP1 protein and inhibiting its interaction with the LASEP1 receptor (LASEPR). This disruption of autocrine and paracrine signaling leads to suppressed growth and reduced motility in lung cancer cells.

Other names
siRNA against LASEP1
02

Targets

LASEP1 (Lung cancer associated serum protein 1)

Beyond the preview

Go deeper on LASEP1 siRNA.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Full profile access

Follow clinical development from study design and recruitment through results.

  • Trial phase
  • Status
  • Readouts

Indications & development

Full profile access

Explore development by indication, patient population, and geography.

  • Indications
  • Development status
  • Countries

Licensing & deals

Full profile access

Trace asset ownership, licensing agreements, and commercial partnerships.

  • Partners
  • Deal terms
  • Milestones

Patents & exclusivity

Full profile access

Explore the patent landscape and regulatory exclusivity around an asset.

  • Patents
  • Expiration dates
  • Exclusivity

Competitive landscape

Full profile access

Compare development programs by target, modality, and indication.

  • Competing assets
  • Targets
  • Development stage

Research & analysis

Full profile access

Connect source evidence and development news to your research questions.

  • Publications
  • News
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on LASEP1 siRNA.

Explore the full profile

Gosset Free

Get started with Gosset.

Enter your work email and we’ll be in touch with next steps.

Work email preferred.

Book a call